清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Vedolizumab in IBD–Lessons From Real-world Experience; A Systematic Review and Pooled Analysis

维多利祖马布 医学 系统回顾 梅德林 政治学 克罗恩病 内科学 疾病 法学
作者
Tal Engel,Bella Ungar,Diana E. Yung,Shomron Ben‐Horin,Rami Eliakim,Uri Kopylov
出处
期刊:Journal of Crohn's and Colitis [Oxford University Press]
卷期号:12 (2): 245-257 被引量:141
标识
DOI:10.1093/ecco-jcc/jjx143
摘要

Vedolizumab [VDZ] is an anti-integrin monoclonal antibody effective in ulcerative colitis [UC] and Crohn's disease [CD]. Several real-world experience [RWE] studies with VDZ have been published to date. The aim of this systematic review was to summarise the available real-life experience with VDZ. We performed a systematic review of the available RWE studies of VDZ in CD and UC. We performed a pooled analysis of the available efficacy and safety data for induction and maintenance treatment in adult cohorts. A narrative review of VDZ use in special clinical settings was also performed. Nine studies including 1565 [571 UC, 994 CD] adult patients were identified. In CD, clinical response and remission were achieved in 54% (95% confidence interval [CI] 41–66%) and 22% [95% CI 13–35%] by Week 6 and in 49% [95% CI 37–51%] and 32% [95% CI 23–42%] by Week 14; at Week 52, 45% [95% CI 28–64%] and 32% [95% CI 12–62] of the patients responded, and were in clinical remission, respectively. In UC, clinical response and remission were achieved in 43% [95% CI 37–49] and 25% [95% CI 12–45] by Week 6, respectively, and in 51% [95% CI 43–61%]and 30% [95% CI 24–36%] by Week 14/22, respectively; at week 52, clinical response and remission were achieved in 48% and 39% of the patients, respectively. Adverse effects were mostly minor and occurred in 30.6% of the patients; infections were reported in 3.4% of the patients. VDZ is efficacious in CD and UC and has a favourable safety profile in RWE studies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LeoBigman完成签到 ,获得积分10
3秒前
文与武完成签到 ,获得积分10
18秒前
昌莆完成签到 ,获得积分10
41秒前
xmhxpz完成签到,获得积分10
47秒前
wack发布了新的文献求助10
1分钟前
1分钟前
搁浅完成签到,获得积分10
1分钟前
zhao完成签到,获得积分10
1分钟前
Hua完成签到,获得积分0
1分钟前
dingding完成签到,获得积分10
1分钟前
月儿完成签到 ,获得积分10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
YifanWang应助科研通管家采纳,获得10
1分钟前
YifanWang应助科研通管家采纳,获得10
1分钟前
YifanWang应助科研通管家采纳,获得40
1分钟前
蔡从安发布了新的文献求助10
1分钟前
糖醋里脊加醋完成签到 ,获得积分10
1分钟前
欢喜白亦完成签到 ,获得积分10
1分钟前
KINGAZX完成签到 ,获得积分10
1分钟前
luckyalias完成签到 ,获得积分10
2分钟前
zhangsan完成签到,获得积分10
2分钟前
2分钟前
雪白小丸子完成签到,获得积分10
2分钟前
www发布了新的文献求助30
2分钟前
蔡从安发布了新的文献求助10
2分钟前
脑洞疼应助蔡从安采纳,获得10
2分钟前
2分钟前
彩色的芷容完成签到 ,获得积分10
3分钟前
东郭凝蝶完成签到 ,获得积分10
3分钟前
宇文非笑完成签到 ,获得积分0
4分钟前
4分钟前
玛卡巴卡爱吃饭完成签到 ,获得积分10
4分钟前
5分钟前
apckkk完成签到 ,获得积分10
5分钟前
5分钟前
YifanWang应助科研通管家采纳,获得20
5分钟前
YifanWang应助科研通管家采纳,获得10
5分钟前
YifanWang应助科研通管家采纳,获得20
5分钟前
默默雪旋完成签到 ,获得积分10
5分钟前
坚强的铅笔完成签到 ,获得积分10
5分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990603
求助须知:如何正确求助?哪些是违规求助? 3532220
关于积分的说明 11256532
捐赠科研通 3271057
什么是DOI,文献DOI怎么找? 1805229
邀请新用户注册赠送积分活动 882302
科研通“疑难数据库(出版商)”最低求助积分说明 809234